Positive quarter from Takeda, waiting for completion of Shire deal

Takeda yesterday announced to the financial community its last six months’ results (Japanese calendar). Sales rose 4.2%, especially thanks to the assets that Takeda itself refers to as “growth drivers”–Gastroenterology, Oncology, Neuroscience and Emerging Markets divisions, which have increased by 9.8%.